Legal Representation
Attorney
Ann Lamport Hammitte
USPTO Deadlines
Application History
39 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jun 14, 2021 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jun 14, 2021 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Dec 1, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 30, 2020 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
| Nov 16, 2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 4, 2020 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
| Nov 4, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 8, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 6, 2020 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
| May 6, 2020 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
| May 6, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 7, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 5, 2019 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Nov 5, 2019 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Nov 5, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 3, 2019 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | Loading... |
| May 1, 2019 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| May 1, 2019 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| May 1, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 6, 2018 | EXRA | O | NOTICE OF APPROVAL OF EXTENSION REQUEST MAILED | Loading... |
| Nov 2, 2018 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Nov 2, 2018 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Nov 2, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 8, 2018 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 13, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 21, 2018 | NPUB | O | NOTICE OF PUBLICATION | Loading... |
| Feb 8, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Aug 8, 2017 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Feb 2, 2017 | RCSC | S | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | Loading... |
| Aug 2, 2016 | CNSL | S | LETTER OF SUSPENSION MAILED | Loading... |
| Aug 1, 2016 | CNSL | R | SUSPENSION LETTER WRITTEN | Loading... |
| Jul 26, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 26, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 26, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jan 27, 2016 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Jan 23, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jan 22, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 7, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Oct 6, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, RNA therapeutics for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection; Pharmaceuticals, biosimilars and biological preparations for medical and therapeutic purposes for use in the treatment of cancer, HIV, hepatitis A, hepatitis B, influenza, measles, neurodegenerative diseases, transthyretin (TTR)-mediated amyloidosis (ATTR), hemophilia, porphyria, complement-mediated disease, hypercholesterolemia, rare genetic diseases, cardio-metabolic diseases, hepatic infectious diseases, hereditary ATTR amyloidosis, rare bleeding disorders, hepatic porphyrias, alpha-1 antitrypsin deficiency, primary hyperoxaluria type 1, beta-thalassemia, iron overload disorders, hereditary angiodema, hypertriglyceridemia, mixed hyperlipidemia, hypertriglyceridemia, hypertension, preeclampsia, thromboprophylaxis, hepatitis B virus infection, hepatitis D virus infection, chronic liver infection
Classification
International Classes
005